Home > Healthcare > Medical Devices > Diagnostic Devices > Chlamydia Infection Diagnostics Market

Chlamydia Infection Diagnostics Market Share

Report ID: GMI11042
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Chlamydia Infection Diagnostics Market Share

The market features a diverse range of companies. Leading corporations are focused on strengthening their market position through new product releases, mergers and acquisitions, and the adoption of cutting-edge technologies.

Chlamydia Infection Diagnostics Market Companies

Some of the eminent market participants operating in the chlamydia infection diagnostics industry include:

Abbott
BD
Bio-Rad Laboratories, Inc.
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd
Hologic, Inc.
QuidelOrtho Corporation.
Siemens Healthineers
Thermo Fisher Scientific Inc.
Trinity Biotech Plc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The chlamydia infection diagnostics industry was valued at USD 1.5 billion in 2023 and is likely to record a 7.1% CAGR through 2032, propelled by technological advancements, increased awareness, and evolving healthcare needs.

The nucleic acid amplification test (NAAT) segment in the market attained USD 668.3 million in 2023 due to their high sensitivity and specificity.

North American chlamydia infection diagnostics market accounted for USD 588.1 million in 2023, amplifying the demand for effective diagnostic solutions to manage and control the spread of the infection.

Abbott, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, and Hologic, Inc., among others.